| AUTOLUS THERAP. SP.ADR/1 |
| USA |
| Gesundheit |
| US05280R1005 / A2JNZJ |
| 6A3A (Frankfurt) / AUTL (NASDAQ) |
| FRA:6A3A, ETR:6A3A, 6A3A:GR, NASDAQ:AUTL |
| - |
| https://www.autolus.com/ |
|
Autolus Therapeutics plc American Depositary Receipt represents shares in Autolus Therapeutics plc, a clinical-stage biopharmaceutical company specializing in next-generation, programmed T cell therap..
>Volltext.. |
| 306.85 Mio. EUR |
| 268.94 Mio. EUR |
| 44.43 Mio. EUR |
| -228.36 Mio. EUR |
| -194.74 Mio. EUR |
| -0.73 EUR |
| 281.89 Mio. EUR |
| 75.96 Mio. EUR |
| -221.02 Mio. EUR |
| 4.44 |
| 407.92% |
| 17.07% |
| - |
| - |
| - |
| - |
| AUTOLUS |
| 27.03.26 |
|